277 related articles for article (PubMed ID: 29027004)
1. Blood lymphocyte subsets identify optimal responders to IFN-beta in MS.
Alenda R; Costa-Frossard L; Alvarez-Lafuente R; Espejo C; Rodríguez-Martín E; de la Maza SS; Villarrubia N; Río J; Domínguez-Mozo MI; Montalban X; Álvarez-Cermeño JC; Villar LM
J Neurol; 2018 Jan; 265(1):24-31. PubMed ID: 29027004
[TBL] [Abstract][Full Text] [Related]
2. Lymphocyte subpopulations, oxidative burst and apoptosis in peripheral blood cells of patients with multiple sclerosis-effect of interferon-beta.
Mix E; Stefan K; Höppner J; Klauer T; Zettl UK; Strauss U; Meyer-Rienecker HJ; Rolfs A
Autoimmunity; 2003 Aug; 36(5):291-305. PubMed ID: 14567559
[TBL] [Abstract][Full Text] [Related]
3. A case study on the effect of neutralizing antibodies to interferon beta 1b in multiple sclerosis patients followed for 3 years with monthly imaging.
Chiu AW; Ehrmantraut M; Richert ND; Ikonomidou VN; Pellegrini S; McFarland HF; Frank JA; Bagnato F
Clin Exp Immunol; 2007 Oct; 150(1):61-7. PubMed ID: 17666095
[TBL] [Abstract][Full Text] [Related]
4. Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?
Uher T; Havrdova E; Sobisek L; Krasensky J; Vaneckova M; Seidl Z; Tyblova M; Ramasamy D; Zivadinov R; Horakova D
Mult Scler; 2017 Feb; 23(2):242-252. PubMed ID: 27230790
[TBL] [Abstract][Full Text] [Related]
5. CD45RA+ ICAM-3+ lymphocytes in interferon-beta1b-treated and -untreated patients with relapsing-remitting multiple sclerosis.
Chatzimanolis N; Kraus J; Bauer R; Engelhardt B; Bregenzer T; Kuehne BS; Tofighi J; Laske C; Stolz E; Blaes F; Voigt K; Traupe H; Kaps M; Oschmann P
Acta Neurol Scand; 2004 Dec; 110(6):377-85. PubMed ID: 15527450
[TBL] [Abstract][Full Text] [Related]
6. Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development.
Hegen H; Millonig A; Bertolotto A; Comabella M; Giovanonni G; Guger M; Hoelzl M; Khalil M; Killestein J; Lindberg R; Malucchi S; Mehling M; Montalban X; Polman CH; Rudzki D; Schautzer F; Sellebjerg F; Sørensen PS; Deisenhammer F
Mult Scler; 2014 Apr; 20(5):577-87. PubMed ID: 24009164
[TBL] [Abstract][Full Text] [Related]
7. Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study.
Boz C; Oger J; Gibbs E; Grossberg SE;
Mult Scler; 2007 Nov; 13(9):1127-37. PubMed ID: 17967840
[TBL] [Abstract][Full Text] [Related]
8. Time-course analysis of CD25 and HLA-DR expression on lymphocytes in interferon-beta 1b-treated multiple sclerosis patients.
Ferrarini AM; Sivieri S; Buttarello M; Facchinetti A; Perini P; Gallo P
Mult Scler; 1998 Jun; 4(3):174-7. PubMed ID: 9762669
[TBL] [Abstract][Full Text] [Related]
9. Neutralizing antibodies to interferon.
Noronha A
Neurology; 2007 Jun; 68(24 Suppl 4):S16-22. PubMed ID: 17562846
[TBL] [Abstract][Full Text] [Related]
10. Effects of interferon-beta on co-signaling molecules: upregulation of CD40, CD86 and PD-L2 on monocytes in relation to clinical response to interferon-beta treatment in patients with multiple sclerosis.
Wiesemann E; Deb M; Trebst C; Hemmer B; Stangel M; Windhagen A
Mult Scler; 2008 Mar; 14(2):166-76. PubMed ID: 17942524
[TBL] [Abstract][Full Text] [Related]
11. Multi-centre validation of a flow cytometry method to identify optimal responders to interferon-beta in multiple sclerosis.
Villarrubia N; Rodríguez-Martín E; Alari-Pahissa E; Aragón L; Castillo-Triviño T; Eixarch H; Ferrer JM; Martínez-Rodríguez JE; Massot M; Pinto-Medel MJ; Prada Á; Rodríguez-Acevedo B; Urbaneja P; Gascón-Gimenez F; Herrera G; Hernández-Clares R; Salgado MG; Oterino A; San Segundo D; Cuello JP; Gil-Herrera J; Cámara C; Gómez-Gutiérrez M; Martínez-Hernández E; Meca-Lallana V; Moga E; Muñoz-Calleja C; Querol L; Presas-Rodríguez S; Teniente-Serra A; Vlagea A; Muriel A; Roldán E; Villar LM
Clin Chim Acta; 2019 Jan; 488():135-142. PubMed ID: 30408481
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis.
Giovannoni G; Barbarash O; Casset-Semanaz F; Jaber A; King J; Metz L; Pardo G; Simsarian J; Sørensen PS; Stubinski B;
Clin Ther; 2007 Jun; 29(6):1128-45. PubMed ID: 17692727
[TBL] [Abstract][Full Text] [Related]
13. CD8+ T cell activation correlates with disease activity in clinically isolated syndromes and is regulated by interferon-beta treatment.
Jensen J; Langkilde AR; Frederiksen JL; Sellebjerg F
J Neuroimmunol; 2006 Oct; 179(1-2):163-72. PubMed ID: 16919783
[TBL] [Abstract][Full Text] [Related]
14. Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS.
Trojano M; Avolio C; Liuzzi GM; Ruggieri M; Defazio G; Liguori M; Santacroce MP; Paolicelli D; Giuliani F; Riccio P; Livrea P
Neurology; 1999 Oct; 53(7):1402-8. PubMed ID: 10534242
[TBL] [Abstract][Full Text] [Related]
15. Natural killer cells in relapsing-remitting MS: effect of treatment with interferon beta-1B.
Kastrukoff LF; Morgan NG; Zecchini D; White R; Petkau AJ; Satoh J; Paty DW
Neurology; 1999 Jan; 52(2):351-9. PubMed ID: 9932956
[TBL] [Abstract][Full Text] [Related]
16. Multiparametric flow cytometric analysis of whole blood reveals changes in minor lymphocyte subpopulations of multiple sclerosis patients.
Teniente-Serra A; Grau-López L; Mansilla MJ; Fernández-Sanmartín M; Ester Condins A; Ramo-Tello C; Martínez-Cáceres E
Autoimmunity; 2016 Jun; 49(4):219-28. PubMed ID: 26829210
[TBL] [Abstract][Full Text] [Related]
17. Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation.
Sellebjerg F; Krakauer M; Hesse D; Ryder LP; Alsing I; Jensen PE; Koch-Henriksen N; Svejgaard A; Soelberg Sørensen P
Eur J Neurol; 2009 Dec; 16(12):1291-8. PubMed ID: 19558503
[TBL] [Abstract][Full Text] [Related]
18. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG).
Rudick RA; Simonian NA; Alam JA; Campion M; Scaramucci JO; Jones W; Coats ME; Goodkin DE; Weinstock-Guttman B; Herndon RM; Mass MK; Richert JR; Salazar AM; Munschauer FE; Cookfair DL; Simon JH; Jacobs LD
Neurology; 1998 May; 50(5):1266-72. PubMed ID: 9595973
[TBL] [Abstract][Full Text] [Related]
19. Immunogenic effects of recombinant interferon-beta therapy disrupt the JAK/STAT pathway in primary immune cells from patients with multiple sclerosis.
Gavasso S; Gjertsen B; Anderssen E; Myhr K; Vedeler C
Mult Scler; 2012 Aug; 18(8):1116-24. PubMed ID: 22287540
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulatory effects of interferon-beta-1b in patients with multiple sclerosis.
Ossege LM; Sindern E; Patzold T; Malin JP
Int Immunopharmacol; 2001 Jun; 1(6):1085-100. PubMed ID: 11407304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
